<DOC>
	<DOCNO>NCT00610740</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Using CerviPrep™ drug delivery device apply topical gemcitabine cervix may effective way kill tumor cell . PURPOSE : This phase II trial study well CerviPrep™ work apply topical gemcitabine cervix treat patient primary endometrial cancer , cervical cancer , ovarian epithelial cancer .</brief_summary>
	<brief_title>CerviPrep Applying Topical Gemcitabine Cervix Treating Patients With Primary Endometrial , Cervical , Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate efficacy CerviPrep™ device deliver topical gemcitabine hydrochloride cervix Secondary - To document side effect directly attribute local administration gemcitabine hydrochloride . OUTLINE : Patients undergo application topical gemcitabine hydrochloride directly cervix use CerviPrep™ drug delivery device routine hysterectomy . Uterine vein peripheral blood sample obtain periodically measure local peripheral gemcitabine hydrochloride concentration level blood . Local gemcitabine hydrochloride concentration level also measure uterine tissue sample obtain surgical specimen hysterectomy . Patients complete self-reported symptom diary first 7 day surgery assessment local systemic side effect associate topical administration gemcitabine hydrochloride . After completion study therapy , patient follow 2-4 week .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Diagnosis primary endometrial cervical cancer Scheduled undergo abdominal hysterectomy part surgical staging and/or treatment Gynecologic Oncology Group ( GOG ) performance status 02 Absolute neutrophil count ( ANC ) ≥ 1,500 cells/mm³ Platelet count ≥ 100,000 cells/mm³ Creatinine ≤ 2.5 mg/dL Serum Aspartate aminotransferase ( AST ) Alanine transaminase ( ALT ) ≤ 3 time upper limit normal Total bilirubin ≤ 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Serious medical condition psychiatric illness place patient unacceptable risk study participation precludes sign informed consent Known allergic reaction hypersensitivity gemcitabine hydrochloride Prior radiotherapy whole abdomen pelvis More 28 day since prior standard experimental anticancer therapy No concurrent anticancer agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>endometrial carcinoma</keyword>
	<keyword>ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
</DOC>